Evaluation of the Dwell-Time and Dose Difference in Intravesical Bacillus Calmette-Guèrin Therapy

Document Type : Research Articles

Authors

1 Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, Japan.

2 Department of Nephro-Urology, Nagoya City University, Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, Japan.

Abstract

Objective: Bacillus Calmette-Guèrin (BCG) intravesical therapy is currently established using a low dose because
of the high incidence of side-effects. Moreover, shortening the dwell time of BCG is conducted in some facilities owing
to the complications associated with a long dwell time after injection. The method of BCG administration varies in
each facility and even with each doctor. We evaluated whether the dwell-time and dose differences in patients who
underwent intravesical BCG therapy is related to completion rates, adverse effects, and nonrecurrence rates. Methods:
From November 2006 to April 2016, a total of 173 patients who received intravesical BCG therapy after transurethral
resection of bladder tumor or transurethral biopsy were evaluated retrospectively. We allocated them into 4 groups based
on the dose (40 or 80 mg BCG) and the dwell time (1 or 2 hours). Completion rate, side effects, and nonrecurrence
rates were evaluated. Results: No significant improvement in the completion rate or reduction in side-effects was
observed in any of the regimens. Although nonrecurrence rates for the 1-hour dwell time tended to be lower than the
2-hour dwell time, the difference was not significant. Conclusion: Our study suggests that reducing the BCG dose or
shortening the dwell time does not reduce adverse effects or affect the nonrecurrence rate.

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention
Volume 20, Issue 5
May 2019
Pages 1389-1392

Files

History

  • Receive Date: 01 October 2018
  • Revise Date: 10 May 2019
  • Accept Date: 21 May 2019

Share

How to cite

Statistics